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Abstract
Background: Maintenance treatment (MTx) in responders following first-line treatment has been investigated and
practiced for many cancers. Modeling and simulation may support interpretation of interim data and development
decisions. We aimed to develop a modeling framework to simulate overall survival (OS) for MTx in NSCLC using
tumor growth inhibition (TGI) data.
Methods: TGI metrics were estimated using longitudinal tumor size data from two Phase III first-line NSCLC studies
evaluating bevacizumab and erlotinib as MTx in 1632 patients. Baseline prognostic factors and TGI metric estimates
were assessed in multivariate parametric models to predict OS. The OS model was externally validated by
simulating a third independent NSCLC study (n = 253) based on interim TGI data (up to progression-free survival
database lock). The third study evaluated pemetrexed + bevacizumab vs. bevacizumab alone as MTx.
Results: Time-to-tumor-growth (TTG) was the best TGI metric to predict OS. TTG, baseline tumor size, ECOG score,
Asian ethnicity, age, and gender were significant covariates in the final OS model. The OS model was qualified by
simulating OS distributions and hazard ratios (HR) in the two studies used for model-building. Simulations of the
third independent study based on interim TGI data showed that pemetrexed + bevacizumab MTx was unlikely to
significantly prolong OS vs. bevacizumab alone given the current sample size (predicted HR: 0.81; 95 % prediction
interval: 0.59–1.09). Predicted median OS was 17.3 months and 14.7 months in both arms, respectively. These
simulations are consistent with the results of the final OS analysis published 2 years later (observed HR: 0.87;
95 % confidence interval: 0.63–1.21). Final observed median OS was 17.1 months and 13.2 months in both arms,
respectively, consistent with our predictions.
Conclusions: A robust TGI-OS model was developed for MTx in NSCLC. TTG captures treatment effect. The model
successfully predicted the OS outcomes of an independent study based on interim TGI data and thus may facilitate
trial simulation and interpretation of interim data. The model was built based on erlotinib data and externally
validated using pemetrexed data, suggesting that TGI-OS models may be treatment-independent. The results
supported the use of longitudinal tumor size and TTG as endpoints in early clinical oncology studies.
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Background
There is still an unmet medical need in the treatment of
non-small cell lung cancer (NSCLC) in both the first-line
and recurrent settings. Maintenance treatment has been
investigated in patients with disease control (i.e. without
progressive disease) during first-line therapy in a number
of trials with the goal to prolong time to disease progres-
sion (progression-free survival, PFS), improve quality of
life and ultimately prolong overall survival (OS) [1–4].
However, the risk-benefit ratio of maintenance therapy in
NSCLC is still unclear, and several aspects of this strategy
have raised considerable debate [2]. Therefore models
that could predict the clinical outcomes of maintenance
therapy may be of great importance to practitioners and
drug developers.
Modeling and simulation may provide quantitative
support for interpretation of interim data and develop-
ment decisions in oncology [5, 6]. Tumor response of pa-
tients can be characterized using tumor growth inhibition
(TGI) metrics, which are estimated based on modeling of
longitudinal tumor size data. TGI metrics have been
shown to predict treatment effect on OS in solid tumors
and in multiple myeloma [5]. These TGI metrics include
model-based estimates of change in tumor size from base-
line at end of cycle 2 (e.g. week 6 or 8), tumor growth rate
and time to tumor regrowth [5]. TGI metrics could be
used as alternative endpoints [7] in early clinical studies to
optimize drug dosing, support clinical trial design for in-
vestigational anti-cancer treatments [5, 6].
Although a few models linking OS with TGI metrics
and prognostic factors have been published for NSCLC
first-line [8–10] and second-line [8] therapies, there has
been no investigation of TGI metrics and of their link
to OS in the context of maintenance therapy to date.
Furthermore, there is insufficient published external
validation of such models. External validation is critical
for assessing treatment independence of the models and
favour acceptance [5]. Finally, the OS models are assumed
to be disease-specific but treatment-independent. How-
ever, to date, there has been insufficient validation of the
treatment-independence assumption.
Accumulation of valuable clinical data has made it
possible to build and externally validate a TGI-OS model
for maintenance therapy in NSCLC patients whose dis-
ease did not progress during first-line therapy. Erlotinib
maintenance prolonged both PFS [11] and OS [12] in
the SATURN trial. The addition of erlotinib to bevacizu-
mab during maintenance therapy significantly prolonged
PFS but not OS compared to the bevacizumab-only
maintenance in the ATLAS trial [13]. The AVAPERL trial
compared maintenance bevacizumab plus pemetrexed vs.
bevacizumab alone and showed a significant prolongation
of PFS [14] but not of OS [15] following bevacizumab plus
pemetrexed compared to bevacizumab alone.
The objectives of this work were 1) to develop a
model for OS after maintenance therapy in NSCLC
based on erlotinib data from SATURN and ATLAS, 2) to
prospectively predict the probability to success of
AVAPERL study and perform an external validation
by simulating the OS outcomes of AVAPERL study
(pemetrexed data) based on interim tumor size data
(up to PFS database lock).
Methods
Trials and data
Data were collected from all patients enrolled in three
studies evaluating maintenance treatment after first-line
NSCLC therapy. In all studies, patients whose disease
did not progress after four cycles of first-line treatment
were randomized to maintenance treatment. Details of
the studies can be found in the respective papers, in the
introduction section and in Table 1. The studies com-
plied with the Declaration of Helsinki and Good Clinical
Practice guidelines, and were approved at all investigat-
ing centers by local ethics committees. All patients pro-
vided written informed consent for participation and
publication of the data [11–15]. An ethics statement was
not required for this analysis as they have been provided
in each of the three individual studies [11–15].
Table 1 Study summary
SATURN [11, 12] ATLAS [13] AVAPERL [14, 15]
Investigational drug Erlotinib Erlotinib Pemetrexed
N: run-in phasea 1949 1145 376
N: maintenance phaseb 889 743 253
N: evaluablec 837 (94 %) 697 (94 %) 231 (94 %)
BTS (cm) 6.99 6.1 5.21
Femaled 26 % 48 % 43 %
ECOG score >0d 69 % 66 % 52 %
Age≥ 55 yearsd 70 % 77 % 72 %
Asiand 15 % 13 % 12 %








BTS baseline tumor size at randomization, ECOG Eastern Cooperative Oncology
Group, TGI tumor growth inhibition
aNumber of patients who received four cycles of first-line treatment
(run-in phase)
bNumber of patients whose disease did not progress during the run-in phase
and who were randomized in the maintenance phase
cNumber of evaluable patients, i.e. patients with at least two tumor size
measurements in the maintenance phase (at least one tumor size
measurement after randomization). The number in the parenthesis represents
the percentage of evaluable patients out of the patients randomized
dThe percentage of patients among evaluable patients
eThe date of “First received” as displayed on ClinicalTrials.gov
Han et al. BMC Cancer  (2016) 16:473 Page 2 of 9
The SATURN trial compared maintenance erlotinib
vs. placebo in patients whose disease did not progress
after four cycles of platinum-based first-line chemother-
apy [11, 12]. The ATLAS trial compared maintenance
erlotinib plus bevacizumab vs. bevacizumab alone in
patients whose disease did not progress after four
cycles of platinum-doublet chemotherapy in combin-
ation with bevacizumab [13]. The AVAPERL trial
compared maintenance bevacizumab plus pemetrexed
vs. bevacizumab alone in patients whose disease did
not progress after four cycles of first-line chemother-
apy of cisplatin plus pemetrexed in combination with
bevacizumab [14, 15].
The following baseline patient characteristics were
tested as prognostic factors for OS based on SATURN and
ATLAS data: age, gender, ethnicity, Eastern Cooperative
Oncology Group (ECOG) score, smoking status, tumor
size, and histology. In addition, study effects and response
to first-line therapy were investigated. Interim AVAPERL
data consisted in longitudinal tumor size collected by the
time of PFS database lock (data cutoff: July 2011) and base-
line patient characteristics only.
Tumor growth inhibition metrics
The full TGI profile was modeled using equations adapted
from previously published simplified TGI models [16]
(Fig. 1) that were fit to data from evaluable patients using
a nonlinear mixed-effect modeling (population) approach
(NONMEM, version 7, FOCE algorithm with interaction)
[17]. To be evaluable in this analysis, patients had to have
at least one tumor size measurement after randomization
to maintenance treatment. Tumor size was assessed as the
sum of longest diameters of target lesions by Response
Evaluation Criteria In Solid Tumors (RECIST) [18, 19].
Shrinkage in model-parameter estimates was estimated as
previously described [20]. Model fitting was assessed using
standard goodness-of-fit plots.
Two patient-level TGI metrics were calculated based on
individual posthoc parameter estimates: the time to tumor
regrowth (TTG) [16], and the week 8 ECTS (early change
in tumor size) that represented early tumor shrinkage and
was calculated as the ratio of model-predicted tumor size
at week 8 to baseline estimated by the model. Equations
are displayed in Fig. 1. Only the TGI metrics during the
maintenance phase were of interest and were calculated.
Fig. 1 Theoretical tumor size profile over first-line treatment run-in phase and maintenance treatment phase. t1: time of randomization to
maintenance treatment; KL: growth rate (assumed to be same during the two treatment phases); TS, KDE and λ: tumor size, drug effect and
drug effect decay over time, respectively, for the first-line (TS1, KDE1 and λ1) and maintenance (TS2, KDE2 and λ2) phase; RND: randomization
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Overall survival model development
Data from SATURN and ATLAS were used to build
the OS model. The impact of individual factors on
OS was assessed using Kaplan-Meier and Cox regression
analyses using survfit and coxph functions, respectively in
R (version 2.15.0) [21]. The baseline patient prognostic
factors together with the TGI metrics were tested to
explain variability in OS.
A parametric survival regression model (using the
survreg function in R version 2.15.0) was developed
that describes OS distribution. The probability density
function that best describes the observed survival
time was selected among normal, lognormal, Weibull,
logistic, log-logistic, and exponential by using difference in
Akaike information criterion (AIC) [22] of the alternative
models.
A “full” model was built by including all significant co-
variates (baseline prognostic factors, TGI metrics) from
the Cox univariate analysis with a significance level of
p < 0.05 per the log-likelihood ratio test where the differ-
ence in −2*log-likelihood (score) between alternative
models follows a χ2 distribution. The score indicates the
level of significance for the association between this covar-
iate and OS: the higher the score, the more significantly
this covariate is associated with OS. Then a backward
stepwise elimination was carried out. At each elimination
step, one covariate was removed from the model. If the re-
duced model (without this removed covariate) became sig-
nificantly worse (p < 0.01), the removed covariate stayed in
the model. The relative influence of each remaining covar-
iate on the model was re-evaluated by deleting it from the
reduced model on an individual basis with a significance
level of p < 0.01. The backward elimination resulted in the
final model, in which all covariates were significant.
The model simulation performances were evaluated
using a posterior predictive check. OS distributions and
hazard ratios (HR) in SATURN and ATLAS were simu-
lated 1000 times. Model parameters were sampled from
the estimated mean values and uncertainty in parameter
estimates for each of the simulated study replicate. Cen-
soring was assumed to be 30 % as in the original data.
Simulations
OS of AVAPERL study were simulated based on TGI
metrics estimated using interim tumor size data to pre-
dict the likelihood of a successful OS outcome for AVA-
PERL and further assess performance of the OS model
(external validation). In order to calculate the prediction
interval and make statistical inferences, the study was
simulated multiple times (20,000) by sampling survival
model parameters from their estimated uncertainty dis-
tribution. Patient survival times were drawn from the
appropriate survival distribution defined by model pa-
rameters, baseline prognostic factors and TGI metric of
AVAPERL patients. Censoring was simulated in sam-
pling patient study duration, assumed to be independent
of death. Patient survival times were censored assuming
a uniform distribution of patient study duration from 50
to 140 weeks, which was consistent with the minimum
and the maximum time period the patient stayed in the
SATURN study without a death event. For each of the
replicates, simulated data were analyzed by Kaplan-
Meier estimation and Cox regression. Kaplan-Meier esti-
mates of OS distributions and HR used to compare both
arms were summarized by median and 95 % prediction
interval (PI) across the replicates.
Results
Data
Patients with at least one post-randomization tumor size
measurement were included in this analysis. Overall
1534 patients were evaluable to estimate TGI metrics
used for building the OS model: 837 (94 %) out of 889
patients from SATURN, and 697 (94 %) out of 743 pa-
tients from ATLAS. Interim AVAPERL data used as the
external validation dataset were collected by the time of
PFS database lock (data cutoff: July 2011) and included
231 evaluable patients out of 245 (94 %) randomized to
maintenance treatment.
Tumor size model
The simplified TGI model adequately described the ob-
served tumor size data, as shown by goodness-of-fit
plots and individual fits (Additional file 1: Figure S1 and
Additional file 2: Figures S2). Parameters were adequately
estimated with small standard errors and shrinkage
(Table 2) except that inter-individual variability could not
be estimated on λ1 due to the limited number of observa-
tions during first-line treatment phase. TGI metric esti-
mates (TTG and week 8 ECTS) that were calculated from
the TGI model parameters (Table 2) using equations dis-
played in Fig. 1 were highly variable: the range from 5th to
Table 2 Parameter estimates of the simplified TGI model
Estimate RSE (%) IIV Shrinkage (%)
KL (week−1) 0.00464 8.59 1.05 25.9
KDE1 (week−1) 0.0566 3.95 0.699 18.3
λ1 (week−1) 0.117 6.06 Fixed to 0
KDE2 (week−1) 0.00412 18.2 1.64 42.1
λ2 (week−1) 0.0597 14.9 0.787 74.3
BASE (cm) 7.74 1.67 0.642 3.5
σ2 (cm2) 0.58 9.14 - 28.8
BASE estimated baseline tumor size, IIV standard deviation of inter-individual
variability, KDE and λ drug effect and drug effect decay over time, respectively
for first-line treatment run-in phase (KDE1 and λ1) and maintenance treatment
phase (KDE2 and λ2), KL growth rate (assumed to be same during the two
treatment phases), RSE relative standard error of parameter estimates, TGI
tumor growth inhibition, σ standard deviation of residual variability
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95th percentile was 0.721 (i.e. decrease in tumor size from
baseline) to 1.24 (i.e. increase in tumor size from baseline)
for week 8 ECTS, and −23 weeks to 70 weeks for TTG
after randomization. TTG may take negative values when
KL > KDE2, i.e. in patients with progression at the
first assessment after randomization to maintenance
phase (Additional file 2: Figure S2).
Overall survival model
In univariate Cox analysis (Table 3), TTG was the most
significant covariate associated with OS (score 151.7) and
much better than week 8 ECTS (score 45.1). The most
significant baseline prognostic factors and patient charac-
teristics were tumor size, gender, smoking status, Asian
ethnicity and ECOG score (scores 8 to 50, p < 0.0001).
Also OS tended to be longer in erlotinib treated patients
and in ATLAS trial compared to SATURN (p < 0.01). OS
distribution by quartiles of TTG is shown in Fig. 2.
A lognormal distribution had the best likelihood to de-
scribe the OS distribution (lower AIC than other distri-
butions). All covariates that were significant in the Cox
univariate analysis were included in the “full” model, and
underwent backward stepwise elimination. The final
model included TTG and the following baseline prog-
nostic factors: baseline tumor size, ECOG score (0 vs.
>0), Asian ethnicity, age and gender. All parameters in
the final OS model were estimated with good precision
(Table 4). According to the model, good prognostic is
predicted for patients with longer TTG (treatment ef-
fect), small baseline tumor size, age below 55 years,
Asian ethnicity, ECOG score 0 and for female patients.
The model was evaluated by simulating OS distribu-
tions in each of the study arms (Fig. 3) and the HR of
treatment vs. control arm in SATURN and ATLAS
(Fig. 4a and b). The observed HR (0.79 for SATURN and
0.93 for ATLAS) was within the 95 % PI by the model
(0.74–0.97 for SATURN and 0.70–1.00 for ATLAS).
Simulation
The final OS model was applied to prospectively predict
the expected OS outcome of AVAPERL study (external
validation). The goal was to predict the likelihood of a
successful OS outcome using interim tumor size data
collected by the time of PFS database lock (data cutoff:
July 2011). This dataset was not used for model-building
(Table 1). Median OS was not yet reached at the time of
data cutoff, and the immature OS data that were ob-
served by the time of data cutoff were not used. Patients
in AVAPERL study had more favorable prognostic factors
than those from SATURN and ATLAS with a smaller pro-
portion of ECOG score >0 (52 % vs. 66–69 %) and smaller
baseline tumor size (5.2 cm vs. >6 cm) (Table 1). Simula-
tions indicated that pemetrexed plus bevacizumab as
maintenance treatment in AVAPERL was unlikely to dem-
onstrate a significant OS prolongation vs. bevacizumab
alone. The expected HR was 0.81 with a 95 % PI of 0.59–
1.09 (62 % of events), which contained 1 (Fig. 4c). Pre-
dicted median OS was 17.3 and 14.7 months in both arms,
respectively. These prospective simulations were consist-
ent with the results of the final OS analysis published re-
cently [15]: the final observed HR was 0.87 with a 95 %
confidence interval of 0.63–1.21 (58 % of events). The
Table 3 Screening of the potential covariates for overall survival using the Cox model
HR 95 % CI Score p Sign on risk
TTG (weeks) 0.83a 0.81–0.85a 151.7 <0.0001 −
Tumor size at randomization (cm) 1.17b 1.13–1.20b 51.8 <0.0001 +
Week 8 ECTS 1.12c 1.10–1.14c 45.1 <0.0001 +
Female 0.64 0.56–0.74 21.2 <0.0001 −
Never smoked 0.57 0.47–0.68 20.3 <0.0001 −
Asian 0.61 0.50–0.75 12.5 <0.0001 −
Study SATURN 1.33 1.16–1.51 9.2 <0.0001 +
ECOG score >0 1.30 1.14–1.49 7.7 0.0001 +
Age≥ 55 years 1.23 1.07–1.42 4.2 0.0037 +
Squamous 1.22 1.06–1.40 3.8 0.0060 +
Erlotinib 0.85 0.75–0.96 3.5 0.0082 −
Erlotinib in SD 0.84 0.73–0.97 3 0.0144 −
Age (years) 1.07d 1.01–1.14d 2.6 0.0221 +
CI confidence interval, ECTS early change in tumor size, Erlotinib patients who received erlotinib during the first-line treatment run-in phase (all patients were
analyzed), Erlotinib in SD patients who received erlotinib during the first-line treatment phase (only those patients who achieved stable disease during first-line
treatment run-in phase were analyzed), HR hazard ratio, p obtained by likelihood ratio test, Score log(likelihood ratio), Sign on risk + (−) indicates that this variable
is associated with increased (decreased) risk, TTG time to tumor regrowth, aHR for increase of every 8 weeks of TTG; bHR for increase of every 2 cm of tumor size
at randomization; cHR for increase in every 10 % of tumor size as compared to the randomization; dHR for increase of every 10 years of age
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final observed median OS was 17.1 and 13.2 months in
both arms, respectively.
Discussion
Maintenance treatment in responders after induction
first-line treatment, without waiting for disease progres-
sion and start of a new line of therapy, is a therapeutic
strategy investigated and used in several tumor types in-
cluding adult and pediatric acute lymphocytic leukemia
[23, 24], follicular non-Hodgkin lymphoma [25, 26],
multiple myeloma [27], breast cancer [28], metastatic
colorectal cancer [29, 30], and advanced ovarian cancer
[31–33]. Although well established for certain hematologic
cancers, maintenance therapy has only recently become a
treatment option for NSCLC [1–3]. The risk-benefit ratio
of maintenance therapy in NSCLC is still unclear, and the
thoracic oncology community has seen considerable de-
bate over several aspects of this strategy [2]. Even when
maintenance treatment allows prolonging PFS and pos-
sibly OS, it is unclear whether OS is prolonged compared
to classical first-line followed by second-line paradigm.
The selection of patients likely to benefit warrants further
research [1–3].
Model-based approaches are gaining momentum to
optimize anti-cancer drug usage and development [6].
Estimates of TGI metrics from modeling of longitudinal
tumor size data have been used to predict clinical out-
comes and simulate clinical trials [5] in variety of settings
including first- and second-line treatment of NSCLC
[8–10]. We present here an adaptation of the modeling
framework for maintenance treatment in NSCLC. The
framework is developed based on two erlotinib mainten-
ance studies and assessed in simulating outcome of an in-
dependent pemetrexed study. As observed in first-line
treatment [9, 10], an estimate of time to tumor regrowth
(TTG) after start of maintenance treatment captured drug
effect, i.e. an OS model incorporating TTG and baseline
prognostic factors was able to simulate erlotinib HR in
SATURN and ATLAS. Baseline prognostic factors in the
model are well known prognostic factors for OS: good
prognostic for patients with small baseline tumor size, age
below 55 years, Asian ethnicity, ECOG score 0 and for fe-
male patients. Smoking status and histology (squamous
vs. non-squamous) that were of significant prognosis
in the univariate analysis were not retained in the final
multivariate model.
As previously discussed [16], the TGI model does not
account for exposure to the treatment drugs and is not
subjected to any simulation-based assessment (e.g. visual
predictive check) because it is not meant to be used for
simulation but only to estimate the TGI metrics to be
used in the OS model. The TGI model could be in other
forms as well, such as a combination of exponential and/
or linear models [8, 34] or a simple spline function.
Therefore the fundamental assumption of constant ex-
posure over time that was previously used [35] to derive
this TGI model from the more complex exposure-driven
model is irrelevant here as the model is not used in
simulations of response for alternative exposure. There is
also no need to assess covariate effects on the TGI model
parameters because the model is not used to simulate
tumor sizes in new patients.
We performed a two-stage analysis, meaning that we
first estimated TGI metrics and then developed the OS
model, and we thereby ignored time-dependent hazard
Fig. 2 Overall survival by quartiles of TTG. Each group represents
25 % of the patients. TTG: time to tumor regrowth (week). OS:
overall survival (week). Median estimates are reported in the insert




(Intercept) 4.3776 0.065883 <0.00001
TTG (weeks) 0.0139 0.000889 <0.00001
BTS (cm) −0.0437 0.005014 <0.00001
Age≥ 55 years −0.2519 0.049494 <0.00001
Asian 0.2324 0.066116 0.00044
ECOG score >0 −0.157 0.045344 0.00054
Female 0.1437 0.045306 0.00151
Log(scale) −0.3017 0.024079 <0.00001
Overall survival was modeled in weeks. A positive (negative) value of the
estimate indicates that an increase (decrease) in the value of this variable is
associated with favorable (unfavorable) overall survival outcome. The p value
was obtained by Wald test (χ2). BTS baseline tumor size at randomization, TTG
time to tumor regrowth
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driven by time-dependent tumor size. In a typical clin-
ical trial setting, tumor size is only observed until dis-
ease progression when treatment is stopped. Median
time of last tumor size observation was 11–18 weeks
while median OS was four times as long (45–63 weeks)
in our model-building dataset. As a result TTG is much
shorter than time to death as shown with the median es-
timates of TTG and OS in Fig. 2. Accounting for tumor
size-dependent hazard would have implied an extrapola-
tion substantially beyond last tumor size observation,
leading to unrealistically large tumor sizes as the model
assumes exponential growth after end of treatment.
Information about subsequent treatments is usually
unavailable, while tumor size-dependent hazard could
only be implemented and evaluated with richer data that
could be obtained during routine care of the patients
across several lines of treatments when tumor size
data could be observed and hazard defined up to patient
death. This approach has been explored with PFS, which
does not suffer this problem [36]. Additionally, simu-
lations have shown that TTG was not confounded
with OS [37, 38].
In the OS model, the censoring model is meant to
mimic the duration (treatment plus follow-up period) a
patient stays in the study if no death event occurs.
The distribution of this duration is defined per proto-
col by the maximum duration of the study and the
patient inclusion rate. If a patient is predicted to die
after his predicted duration in the study, this patient
is censored. The distribution of study duration is
Fig. 3 Posterior predictive check of the final OS model by studies: a) SATURN and b) ATLAS. Solid line: observed OS. Band: 95 % prediction
interval of OS. OS: overall survival
Fig. 4 Posterior predictive check of HR in SATURN (a) and ATLAS (b) for maintenance erlotinib compared to placebo and simulation of HR in AVAPERL
(c) for maintenance pemetrexed vs. placebo and comparison to observed HR. CI: confidence interval. HR: hazard ratio. PI: prediction interval
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independent of OS and TGI data and doesn’t require
simultaneous modeling.
Another limitation of our analysis is that patients
needed to have at least two tumor size measurements in
the maintenance phase to be evaluable in the TGI model
because the TGI parameters were unidentifiable with only
one tumor size measurement. These excluded patients
who died or dropped out of the study early before the first
tumor size measurement may have rapidly growing tu-
mors. However, this may not have a significant impact on
this analysis because 94 % of the patients were evaluable.
The model successfully simulated the OS outcomes of
the pemetrexed maintenance study AVAPERL based on
interim tumor size data collected by the time of PFS
database lock before median OS was even reached. This
is the first modeling framework for maintenance treatment
and one of the few such frameworks validated in simulat-
ing an independent study with a drug with a different
mechanism of action (pemetrexed) compared to the one
used to develop the model (erlotinib), providing support to
the hypothesis that TGI metrics capture drug effect inde-
pendent of treatment [5]. This framework may be used to
support design and interim analysis of upcoming mainten-
ance studies and to help in the selection of patients most
likely to benefit from maintenance treatment.
Conclusion
In conclusion, a robust TGI-OS model linking OS
with TGI metrics and prognostic factors was developed
for maintenance therapy following first-line NSCLC treat-
ment. The model successfully predicted the OS outcomes
of an independent study (AVAPERL) based on interim
tumor size data (up to PFS database lock), indicating that
the model may be used for trial simulation and facilitate
interpretation of interim data and development decisions.
The model was built based on erlotinib data and exter-
nally validated using pemetrexed data, suggesting that
TGI-OS models may be treatment-independent. The re-
sults also supported the use of longitudinal tumor size
and TTG as endpoints in early clinical oncology studies.
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